New Drug Product Slideshows

Stiolto Respimat

Long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

Evekeo

Attention deficit hyperactivity disorder (ADHD). Narcolepsy. Short-term adjunct in managing exogenous obesity.

Zerbaxa

Susceptible complicated intra-abdominal infections in combination with metronidazole and complicated urinary tract infections, including pyelonephritis.

Unituxin

In combination with granulocyte-macrophage colony-stimulating factor, interleukin-2 (IL-2) and 13-cis-retinoic acid (RA), for the treatment of children with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy.

Cosentyx

Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

ProAir RespiClick

Treatment or prevention of bronchospasm in patients ≥12 years of age with reversible obstructive airway disease. Prevention of exercise-induced bronchospasm in patients ≥12 years of age.

Farydak

Multiple myeloma, in patients who have received at least two prior regimens (including bortezomib and an immunomodulatory agent), in combination with bortezomib and dexamethasone.

Evotaz

HIV-1 infection in combination with other antiretroviral agents.

New Products

NAMZARIC

  • 8/2/2015
  • Actavis
  • Memantine HCl extended-release, donepezil HCl; 14mg/10mg, 28mg/10mg; capsules.
  • Moderate-to-severe dementia of the Alzheimer's type in patients stabilized on memantine HCl and donepezil HCl.
STIOLTO RESPIMAT

STIOLTO RESPIMAT

  • 7/26/2015
  • Boehringer Ingelheim Pharmaceuticals
  • Tiotropium 2.5mcg, olodaterol 2.5mcg; per actuation; inhalation spray; contains benzalkonium chloride.
  • Long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Limitations of use: not for treating asthma or acute deteriorations of COPD.

EVEKEO

  • 7/19/2015
  • Arbor Pharmaceuticals, Inc.
  • Amphetamine sulfate 5mg, 10mg; tablets.
  • Attention deficit hyperactivity disorder (ADHD). Narcolepsy. Short-term adjunct in managing exogenous obesity.
ZERBAXA

ZERBAXA

  • 7/12/2015
  • Merck Co., Inc.
  • 1.5g (ceftolozane 1g and tazobactam 0.5g); per vial; pwd for IV infusion after reconstitution; preservative-free; contains sodium chloride 487mg/vial.
  • Susceptible complicated intra-abdominal infections in combination with metronidazole and complicated urinary tract infections, including pyelonephritis.

UNITUXIN

  • 7/7/2015
  • United Therapeutics Corp.
  • Dinutuximab 3.5mg/mL; solution for IV infusion after dilution; preservative-free.
  • In combination with granulocyte-macrophage colony-stimulating factor, interleukin-2 (IL-2) and 13-cis-retinoic acid (RA), for the treatment of children with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy.
COSENTYX

COSENTYX

  • 6/28/2015
  • Novartis Pharmaceuticals Corp
  • Secukinumab 150mg/mL; soln for SC inj; and lyophilized pwd for SC inj after reconstitution; preservative-free.
  • Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

PROAIR RESPICLICK

  • 6/21/2015
  • Teva Pharmaceuticals
  • Albuterol sulfate 90mcg/inh; dry pwd for oral inhalation with a dose counter.
  • Treatment or prevention of bronchospasm in patients ≥12 years of age with reversible obstructive airway disease. Prevention of exercise-induced bronchospasm in patients ≥12 years of age.
FARYDAK

FARYDAK

  • 6/14/2015
  • Novartis Pharmaceuticals Corp
  • Panobinostat 10mg, 15mg, 20mg; capsules.
  • Multiple myeloma, in patients who have received at least two prior regimens (including bortezomib and an immunomodulatory agent), in combination with bortezomib and dexamethasone.
EVOTAZ

EVOTAZ

  • 6/7/2015
  • BristolMyers Squibb
  • Atazanavir 300mg, cobicistat 150mg; tablets.
  • HIV-1 infection in combination with other antiretroviral agents. Limitations of use: guide use in treatment-experienced patients by number of baseline primary protease inhibitor resistance substitutions.
PREZCOBIX

PREZCOBIX

  • 5/29/2015
  • Janssen Pharmaceuticals, Inc.
  • Darunavir 800mg, cobicistat 150mg; tabs.
  • In combination with other antiretroviral agents for treatment of HIV-1 infection in adults with no darunavir resistance-associated substitutions (V11I, V32I, L33F, I47V, I50V, I54L, I54M T74P, L76V, I84V, L89V).

CRESEMBA

  • 5/24/2015
  • Astellas Pharma US, Inc.
  • Isavuconazonium sulfate 186mg capsules; and 372mg/vial lyophilized powder for IV injection after reconstitution; preservative-free.
  • Invasive aspergillosis. Invasive mucormycosis.
IBRANCE

IBRANCE

  • 5/17/2015
  • Pfizer Inc.
  • Palbociclib 75mg, 100mg, 125mg; capsules.
  • In combination with letrozole, for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for metastatic disease.
SAXENDA

SAXENDA

  • 5/10/2015
  • Novo Nordisk
  • Liraglutide [rDNA origin] 6mg/mL; soln for SC inj.
  • Adjunct to reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial BMI of ≥30kg/m2 (obese), or ≥27kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (eg, hypertension, T2DM, dyslipidemia). Limitations of use: not indicated for type 2 diabetes. Do not use with Victoza, other GLP-1 receptor agonists, or insulin. Effects on cardiovascular morbidity and mortality have not been established. Safety and efficacy with concomitant other weight loss products has not been established. Not studied in patients with history of pancreatitis.
OPDIVO

OPDIVO

  • 5/3/2015
  • BristolMyers Squibb
  • Nivolumab 10mg/mL; per vial; soln for IV infusion after dilution; preservative-free; contains mannitol.
  • Unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. Metastatic squamous non-small cell lung cancer with progression on or after platinum-based chemotherapy.
MOVANTIK

MOVANTIK

  • 4/26/2015
  • AstraZeneca Pharmaceuticals
  • Naloxegol 12.5mg, 25mg; tablets.
  • Opioid-induced constipation in adults with chronic non-cancer pain.
GLYXAMBI

GLYXAMBI

  • 4/19/2015
  • Boehringer Ingelheim and Lilly
  • Empagliflozin, linagliptin; 10mg/5mg, 25mg/5mg; tablets.
  • Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and linagliptin is appropriate. Limitations of use: not for treating type 1 diabetes or diabetic ketoacidosis. Not studied in patients with a history of pancreatitis.
LENVIMA

LENVIMA

  • 4/12/2015
  • Eisai Pharmaceuticals
  • Lenvatinib 4mg, 10mg; capsules.
  • Treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer.

SAVAYSA

  • 4/5/2015
  • Daiichi Sankyo
  • Edoxaban 15mg, 30mg, 60mg; tablets.
  • To reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5–10 days of initial therapy with parenteral anticoagulant. Limitations of use: not for use in NVAF patients with CrCl >95mL/min.
BELSOMRA

BELSOMRA

  • 3/29/2015
  • Merck Co., Inc.
  • Suvorexant 5mg, 10mg, 15mg, 20mg; tablets.
  • Treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.
RAPIVAB

RAPIVAB

  • 3/22/2015
  • BioCryst Pharmaceuticals, Inc.
  • Peramivir 10mg/mL; per vial; solution for IV injection after dilution; preservative-free.
  • Treatment of acute uncomplicated influenza in patients who have been symptomatic for ≤2 days. Limitations of use: Efficacy based on predominantly influenza A virus infections; limited number of influenza B virus subjects enrolled. Consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use. Efficacy not established in serious influenza requiring hospitalization.